Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies
CNS Neuroscience & Therapeutics · 2024-11 · 30 (11)
DOI: 10.1111/cns.70050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 11.11.2024. Verfasst von Paloma García Quilón und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Epilepsy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Developmental and epileptic encephalopathies (DEEs) comprise a complex spectrum of neurological disorders characterized by neurodevelopmental delay and early‐onset seizures primarily caused by diverse genetic mutations. Traditional treatments have largely been symptomatic, focusing on seizure control without addressing the underlying genetic causes. The advent of gene therapy, particularly through antisense oligonucleotides (ASOs), offers a promising avenue toward targeted therapeutic interventions. ASOs by virtue of their ability to modulate gene expression at the mRNA level represent a sophisticated approach to counteract the effects of pathogenic mutations. This review delves into the recent advancements in ASO technology, highlighting its application in preclinical and clinical settings for DEEs. We present evidence of the efficacy of ASOs in ameliorating disease phenotypes in vitro and in vivo, alongside promising outcomes from ongoing clinical trials. The therapeutic landscape for DEEs is on the cusp of significant transformation, underscored by the potential of ASOs to offer precise, personalized, treatments that extend beyond symptomatic relief to potentially rectify the genetic underpinnings of these disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
- Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
ORCID-Profile: Antonella Riva
Zitieren
APA
Quilón, P. G., Volpedo, G., Cappato, S., Ferrera, L., Zara, F., Bocciardi, R., Riva, A., & Striano, P. (2024). Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies. CNS Neuroscience & Therapeutics, 30(11). https://doi.org/10.1111/cns.70050
Vancouver
Quilón PG, Volpedo G, Cappato S, Ferrera L, Zara F, Bocciardi R, et al. Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies. CNS Neuroscience & Therapeutics. 2024;30(11). doi:10.1111/cns.70050
BibTeX
@article{Quiln2024,
author = {Quilón, Paloma García and Volpedo, Greta and Cappato, Serena and Ferrera, Loretta and Zara, Federico and Bocciardi, Renata and Riva, Antonella and Striano, Pasquale},
title = {Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {11},
doi = {10.1111/cns.70050}
}
EUVIMED